

FOR IMMEDIATE RELEASE

Bulgaria successfully implements the industry's first integrated Biomarker Generator for clinical PET.

Knoxville, TN, UNITED STATES, September 6, 2013 – Sveta Marina University Hospital in Varna, Bulgaria has demonstrated the clinical utility and ease of implementation of ABT's next-generation product, the "Dose on Demand Biomarker Generator, integrating a compact accelerator, micro-chemistry, and automated quality control, for single-dose FDG production.

Sveta Marina has produced over 500 clinical doses on the ABT System following initial installation in April, 2013. "The ABT Biomarker Generator System has enabled us to produce our own supply of FDG, making our operations much more efficient and cost effective", stated Prof. Pavel Bochev, Head of the Nuclear Medicine Department. "We were able to fully implement the ABT solution within eight months of our bid tender, and utilize our existing staff, which is an important advantage of the system. The image quality provided by the ABT System, and our Philips Time of Flight PET/CT Scanner, is excellent."

"We see Sveta Marina's success as an important milestone for the implementation of clinical PET worldwide. Emerging markets have been forced to delay integration of PET services due to the constraints in FDG availability, and the complexity of conventional solutions for in-house production", said Peter Kingma, President and CEO of ABT Molecular Imaging. "The Biomarker Generator provides a fully integrated, compact and affordable solution to address this issue."

Sveta Marina University Hospital is the largest diagnostic and consultative medical university complex in Varna. The hospital partnered with Molecular Solutions Bulgaria (MSB), an official representative of ABT for the region dedicated to bridging the gap between medical innovations and the healthcare sector in developing countries.

About ABT Molecular Imaging, Inc: ABT Molecular Imaging is a medical imaging company marketing the Biomarker Generator-75, which produces unit doses of molecular imaging drugs for positron emission tomography (PET) at the point of use. The company was founded in 2006 by industry experts in the molecular imaging industry. ABT's investor partners include Intersouth Partners, River Cities Capital and two TNInvestco Funds, Council & Enhanced Tennessee Fund and Limestone Fund.

For all media enquires please contact:

Rick Rippin, Director of Sales

Telephone: 407-615-0776/Email: rrippin@abt-mi.com

The Company is headquartered in Knoxville, Tennessee. For more information visit www.advancedbiomarker.com

###